Skip to main content
AtriCure, Inc. logo

AtriCure, Inc. — Investor Relations & Filings

Ticker · ATRC ISIN · US04963C2098 LEI · 254900B2I6GPHK2EXM59 US Manufacturing
Filings indexed 1,189 across all filing types
Latest filing 2013-04-18 Annual Report
Country US United States of America
Listing US ATRC

About AtriCure, Inc.

https://www.atricure.com

AtriCure, Inc. is a medical device company focused on developing, manufacturing, and selling technologies for the treatment of atrial fibrillation (Afib), management of the left atrial appendage (LAA), and post-operative pain. The company's product portfolio is primarily utilized by cardiothoracic surgeons and electrophysiologists. Key offerings include surgical ablation systems and the AtriClip® LAA Exclusion System, a widely implanted device for LAA management. Additionally, AtriCure provides cryoablation technology, such as the cryoXT™ Probe, which offers a non-opioid approach to pain management following surgical procedures, including amputation.

Recent filings

Filing Released Lang Actions
AUTO-GENERATED PAPER DOCUMENT
Annual Report
2013-04-18 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2013-04-12 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 29, 2013, by AtriCure, Inc. It reports the entry into a material definitive agreement, specifically loan modification agreements with Silicon Valley Bank, including changes to borrowing rates and financial covenants. The document includes descriptions of the agreements and references exhibits containing the full agreements. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The content focuses on financing activity and credit facility amendments. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 3612 characters, which is consistent with a detailed announcement rather than a brief notice or a full report. Confidence is high due to the clear description of loan modifications and credit facility changes.
2013-03-29 English
SCHEDULE 13D (AMENDMENT NO. 4)
Major Shareholding Notification
2013-03-26 English
FORM 4/A
Director's Dealing
2013-03-15 English
FORM 4
Director's Dealing
2013-03-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.